IM Cannabis Corp

IM Cannabis Corp(IMCC)股票分析

$1.190

-0.179 (-15.00%)收盘时

Loading chart…
最高
1.395
开盘
1.370
成交量加权均价
1.24
成交量
130.04K
市值
6.03M
最低
1.130
成交额
161.04K
企业价值/息税折旧摊销前利润(TTM)
-0.65

IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower.

AI 分析 of IM Cannabis Corp (IMCC)

卖出

IM Cannabis Corp. is not a good buy right now due to its significant financial struggles and negative market sentiment. The stock has dropped 96.89% year-to-date, and the current RSI is at 27.00, indicating it is oversold but still under pressure. Additionally, the company reported a net income loss of CAD 4.36 million in Q2 2026, which raises concerns about its profitability and sustainability.

估值指标

IM Cannabis Corp(IMCC)当前预期市盈率为 42.37,5 年平均预期市盈率为 -0.17。

预期市盈率

高估
5 年均值 P/E
-0.17
当前P/E
42.37
高估
38.56
低估
-38.90

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-5.88
当前EV/EBITDA
-0.65
高估
19.36
低估
-31.12

预期市销率

合理
5 年均值 P/S
0.44
当前P/S
0.03
高估
1.18
低估
-0.30

Alphio AI 对 IMCC 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%IMCC

$3.63

情景价格

基

基准

基准 · 50%IMCC

$3.29

情景价格

悲

悲观

悲观 · 25%IMCC

$3.15

情景价格

事件时间线

2026-10-08 (ET)

16:30:00

Selling Stockholders Offer 2.8M Common Shares

2026-09-23 (ET)

09:00:00

IM Cannabis Issues 655,000 Shares at $2 Each

08:00:00

IM Cannabis Signs LOI to Acquire 51% Stake in Space Defense

2026-08-26 (ET)

20:00:00

IM Cannabis Trading Halted, News Pending

2026-06-18 (ET)

08:00:00

IM Cannabis Signs LOI with Slil.com to Sell European Assets

资讯

IMCC 常见问题 —— 由 Alphio AI 解答

IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower. It operates in the Consumer Non-Cyclicals sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).

IM Cannabis Corp. is not a good buy right now due to its significant financial struggles and negative market sentiment. The stock has dropped 96.89% year-to-date, and the current RSI is at 27.00, indicating it is oversold but still under pressure. Additionally, the company reported a net income loss of CAD 4.36 million in Q2 2026, which raises concerns about its profitability and sustainability.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易